Literature DB >> 28076715

Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.

Richard Barnett1, Valerie S Barta1, Kenar D Jhaveri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28076715     DOI： 10.1056/NEJMc1614298

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  37 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 2.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 3.  Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.

Authors:  Fedaey Abbas; Mohsen El Kossi; Ihab Sakr Shaheen; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2020-02-28

4.  Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma.

Authors:  Andreas Varkaris; David W Lewis; Francis W Nugent
Journal:  Am J Gastroenterol       Date:  2017-12       Impact factor: 10.864

5.  Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

Authors:  Luis E Aguirre; Maria E Guzman; Gilberto Lopes; Judith Hurley
Journal:  Oncologist       Date:  2018-11-09

Review 6.  Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.

Authors:  J Claveau; J Archambault; D S Ernst; C Giacomantonio; J J Limacher; C Murray; F Parent; D Zloty
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

7.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 8.  Cutaneous squamous cell carcinoma in the organ transplant recipient.

Authors:  Kristin Bibee; Andrew Swartz; Shaum Sridharan; Cornelius H L Kurten; Charles B Wessel; Heath Skinner; Dan P Zandberg
Journal:  Oral Oncol       Date:  2020-02-14       Impact factor: 5.337

Review 9.  Programmed T cell differentiation: Implications for transplantation.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Cell Immunol       Date:  2020-03-29       Impact factor: 4.868

10.  Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.

Authors:  Kang Miao; Li Zhang
Journal:  Interdiscip Sci       Date:  2021-06-21       Impact factor: 2.233
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.